Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 19Docetaxel 9atezolizumab 8Cetuximab 8Nivolumab 7cemiplimab 6Ipilimumab 4Immune Checkpoint Inhibitors 4Gemcitabine 4Drug Therapy 4spartalizumab 3palbociclib 3fludarabine 3durvalumab 3avelumab 3Trastuzumab 3Radiotherapy 3Paclitaxel 3Oncolytic Virotherapy 3Irinotecan 3Fulvestrant 3Fluorouracil 3Cyclophosphamide 3Carboplatin 3Bortezomib 3Blood Specimen Collection 3seribantumab 2selpercatinib 2pazopanib 2motexafin gadolinium 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × amivantamab × Breast × Clear all
NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡